Overall, AKT inhibitors have shown a lack of correlation between PI3K/AKT pathway alterations and efficacy of AKT inhibitors from HR+ BC patients with limited data available on HER2+ and a positive trend in TNBC patients. Here, ERBB2 is linked to breast cancer.